BRAF/MEK Inhibitor Therapy Consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events and potential drug interactions

摘要

BACKGROUND: BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E-and V600K-mutated unresectable or metastatic melanoma. However, these regimens are associated with adverse events (AEs) that may lead to unnecessary drug modifications and discontinuations or potentially serious sequelae. In addition, drug-drug interactions (DDIs) may result in AEs or altered therapeutic efficacy.